Skip to main content

Stage groupings

FIGO Stage

Description

I

The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded).

IA - Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion <5 mma.

IA1 - Measured stromal invasion ≤3 mm in depth.

IA2 - Measured stromal invasion >3 mm and ≤5 mm in depth.

IB - Invasive carcinoma with measured deepest invasion >5 mm (greater than stage IA); lesion limited to the cervix uteri with size measured by maximum tumour diameterb

IB1 - Invasive carcinoma >5 mm depth of stromal invasion and ≤2 cm in greatest dimension.

IB2 Invasive carcinoma >2 cm and ≤4 cm in greatest dimension.

IB3 Invasive carcinoma >4 cm in greatest dimension.

II

The carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall.

IIA - Involvement limited to the upper two‐thirds of the vagina without parametrial involvement.

IIA1 - Invasive carcinoma ≤4 cm in greatest dimension.

IIA2 - With parametrial involvement but not up to the pelvic wall.

III

The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non‐functioning kidney and/or involves pelvic and/or paraaortic lymph nodes.

IIIA - Carcinoma involves the lower third of the vagina, with no extension to the pelvic wall.

IIIB - Extension to the pelvic wall and/or hydronephrosis or non‐functioning kidney (unless known to be due to another cause).

IIIC - Involvement of pelvic and/or paraaortic lymph nodes (including micrometastases)c, irrespective of tumour size and extent (with r and p notations) d

IIIC1 - Pelvic lymph node metastasis only.

IIIC2 - Paraaortic lymph node metastasis.

IV

The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to stage IV.

IVA - Spread of the growth to adjacent organs.

IVB - Spread to distant organs.

Notes:

a Imaging and pathology can be used, when available, to supplement clinical findings with respect to tumour size and extent, in all stages. Pathological findings supersede imaging and clinical findings.

b The involvement of vascular/lymphatic spaces should not change the staging. The lateral extent of the lesion is no longer considered.

c Isolated tumour cells do not change the stage but their presence should be recorded.

d Adding notation of r (imaging) and p (pathology), to indicate the findings that are used to allocate the case to stage IIIC. For example, if imaging indicates pelvic lymph node metastasis, the stage allocation would be Stage IIIC1r; if confirmed by pathological findings, it would be Stage IIIC1p. The type of imaging modality or pathology technique used should always be documented. When in doubt, the lower staging should be assigned.


Download

Click on the box below to download a PDF version of this data sheet:

Last edited: 21 December 2022 5:35 pm

  1. Cancer staging guidance sheets
  2. Lip and oral cavity (ICD10 C00, C02-C06)
  3. Malignant melanoma of upper aerodigestive tract (ICD10 C00-06, C10-14, C30-32)
  4. Pharynx (ICD10 C01, C05.1-2, C09, C10.0, C10.2-3, C11-13)
  5. Major salivary glands (ICD10 C07, C08)
  6. Oesophagus including oesophagastric junction (ICD10 C15 & C16.0)
  7. Stomach (ICD10 C16 except C16.0)
  8. Small intestine (ICD10 C17)
  9. Appendix (ICD10 C18.1)
  10. Colon and rectum (ICD10 C18-C20)
  11. Anal canal and perianal skin data (ICD10 C21, C44.5)
  12. Liver (ICD10 C22.0)
  13. Intrahepatic bile ducts (ICD10 C22.1)
  14. Gallbladder (ICD10 C23, C24.0)
  15. Distal extrahepatic bile duct (ICD10 C24.0)
  16. Perihilar bile ducts (ICD10 C24.0)
  17. Ampulla of vater (ICD10 C24.1)
  18. Pancreas (ICD10 C25)
  19. Nasal cavity and paranasal sinuses (ICD10 C30.0, C31.0, C31.1)
  20. Larynx (ICD10 C32.0 C32.1, C32.2, C10.1)
  21. Lung (ICD10 C34)
  22. Thymic tumours (ICD10 C37)
  23. Soft tissues (ICD10 C38.1-2, C47-C49)
  24. Bone (ICD10 C40 & C41)
  25. Malignant melanoma of skin (ICD10 C43, C51.0, C60.9, C63.2)
  26. Merkel cell carcinoma of skin (ICD10 C44 & C63.2)
  27. Skin carcinoma of the head and neck (ICD10 C44.0, C44.2-4)
  28. Carcinoma of skin of the eyelid (ICD10 C44.1)
  29. Carcinoma of skin (excluding eyelid, head and neck, perianal, vulva and penis) (ICD10 C44.5-7, C63.2)
  30. Pleural mesothelioma (ICD10 C45)
  31. Breast tumours (ICD10 C50)
  32. Vulva (ICD10 C51)
  33. Cervix uteri (ICD10 C53)
  34. Uterine sarcomas
  35. Uterus - endometrium (ICD10 C54.1, C55)
  36. Ovarian, fallopian tube and primary peritoneal carcinoma (ICD10 C56, C57, C48.1, C48.2)
  37. Gestational trophoblastic neoplasms (ICD10 C58)
  38. Penis tumours (ICD10 C60)
  39. Prostate tumours (ICD10 C61)
  40. Testis tumours (ICD10 C62)
  41. Kidney tumours (ICD10 C64)
  42. Renal pelvis and ureter tumours (ICD10 C65 & C66)
  43. Urinary bladder tumours (ICD10 C67)
  44. Urethra tumours (ICD10 C68.0)
  45. Carcinoma of conjuctiva (ICD10 C69.0)
  46. Malignant melanoma of conjuctiva (ICD10 C69.0)
  47. Retinoblastoma (ICD10 C69.2)
  48. Malignant melanoma of uvea (ICD10 C69.3, C69.4)
  49. Carcinoma of lacrimal gland (ICD10 C69.5)
  50. Sarcoma of orbit (ICD10 C69.6)
  51. Thyroid gland (ICD10 C73)
  52. Adrenal cortex (ICD10 C74.0)
  53. Chronic lymphocytic leukaemia
  54. Hepatoblastoma (CTYA)
  55. Hodgkins and non-hodgkins lymphoma (ICD10 C81-88)
  56. Medulloblastoma
  57. Multiple myeloma
  58. Neuroblastoma
  59. Neuroendocrine tumours of the foregut
  60. Neuroendocrine tumours of the midgut and hindgut
  61. Non-hodgkin lymphoma (children)
  62. Rhabdomyosarcoma and other soft tissue sarcomas (CTYA)
  63. Wilms tumour of the kidney